Sensitivity and specificity of epstein‐barr virus I<scp>G</scp>A titer in the diagnosis of nasopharyngeal carcinoma: a three‐year institutional review

Tsang, Raymond K. Y.; Vlantis, Alexander C.; Ho, Rosalie; Tam, John S.; To, Ka Fai; Hasselt, C. Andrew van

doi:10.1002/hed.20022

Cited by 45 publications

(34 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After the human body is infected, EA-IgG and VCA-IgG will peak in 5 weeks and EBNA1-IgG in 5 months. At present, the high false positive rate of the screening biomarker and low sensitivity of the diagnosis biomarker make accurate early diagnosis of NPC difficult (Tsang et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

EA-D p45-IgG as a Potential Biomarker for Nasopharyngeal Carcinoma Diagnosis

Chen

Luo²,

Zhang³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

EA-D p45-IgG as a Potential Biomarker for Nasopharyngeal Carcinoma Diagnosis

Chen

Luo²,

Zhang³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…1 Although several previous studies [2][3][4][5] have reported on the use of EBV serology for screening and early detection of NPC, the role of EBV DNA detection as a screening test for NPC remains to be defined. Circulating cell-free EBV DNA is detectable in the plasma of 96% of NPC patients 6 by quantitative real-time polymerase chain reaction (PCR) and has been shown to be a useful marker in prognostication 7 as well as residual disease detection.…”

Section: Dear Sirmentioning

confidence: 99%

Plasma Epstein‐Barr virus (EBV) DNA: Role as a screening test for nasopharyngeal carcinoma (NPC)?

Wong

Lai

Tsui

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Dear Sir,We read with interest the recent article in this journal on screening for family members of nasopharyngeal carcinoma (NPC) patients by serologic tests against Epstein-Barr virus (EBV). 1 Although several previous studies [2][3][4][5] have reported on the use of EBV serology for screening and early detection of NPC, the role of EBV DNA detection as a screening test for NPC remains to be defined. Circulating cell-free EBV DNA is detectable in the plasma of 96% of NPC patients 6 by quantitative real-time polymerase chain reaction (PCR) and has been shown to be a useful marker in prognostication 7 as well as residual disease detection. 8 Studies on EBV DNA detection, however, are performed on known NPC patients but not in the general population. We report our preliminary results on plasma EBV DNA detection, in association with EBV serology, as screening tests for NPC in the setting of routine health assessment.In the 6-month period from July to December 2004, a total of 1,475 blood samples were referred from the Health Assessment Centre of our hospital for detection of EBV status as part of body checkup. They comprised 875 male patients and 600 female patients with a median age of 49 years (range 16-92 years). None of them had prior history of EBV-related malignancies. All patients were tested for cell-free plasma EBV DNA level, and when the result was positive, serum samples were retrieved for EBV serologic testing.The RealArt EBV LC PCR Kit (Artus, Hamburg, Germany), working on the LightCycler instrument (Roche Diagnostics, Mannheim, Germany), was employed for plasma EBV DNA detection. The EBV LC PCR Master reagent contained reagents and enzymes for the specific amplification of a 97 bp region of the EBNA1 gene of the EBV genome. Quantification standards were provided with the kit and were included in each run so as to generate the standard curve for EBV load determination. An external quantified EBV viral DNA control (Advanced Biotechnologies, Columbia, MD) was included in each run to check the performance of the assay. Serum EBV VCA IgA and EA IgA antibody levels were determined by indirect immunofluorescence assay on Raji cells and B95-8 cells induced to express EA and VCA, respectively (purchased from the Department of Microbiology, The University of Hong Kong). Antibody titer was defined as the highest dilution that yielded a positive fluorescent signal. Cutoff values for positivity were set at 1:40 for VCA IgA and 1:10 for EA IgA.The presence of EBV DNA was detected in 33 patients (2.24%). Among them, 4 were positive for VCA IgA in which 1 patient was also positive for EA IgA. The clinical records of these patients were reviewed. The only patient with detectable EBV DNA (118 copies/mL) and positive VCA (titer 1:80) as well as EA (titer 1:40) IgA was a 48-year-old man who was referred for otorhinolaryngology (ENT) consultation. Endoscopic examination of the nasopharynx and biopsy showed undifferentiated carcinoma consistent with NPC. Another patient, a 20-year-old man who showed detectable EBV DNA (4...

show abstract

“…Although several prior studies (Zeng et al, 1982;Zeng et al, 1983;Zeng et al, 1985;Tsang et al, 2004) have demonstrated on the use of EBV serology for screening and early detection of NPC, the role of EBV DNA detection as a screening test for NPC remains inconclusive. Previous research has reported that cell-free EBV DNA can be quantitatively measured in the blood of NPC patients using polymerase chain reaction (PCR) technique Shotelersuk et al, 2000;Lin et al, 2001;Chan et al, 2003;Fan et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Systematic Review on Epstein-Barr Virus (EBV) DNA in Diagnosis of Nasopharyngeal Carcinoma in Asian Populations

Han¹,

Xu²,

Zhang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Sensitivity and specificity of epstein‐barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three‐year institutional review

Abstract: Although the EBV IgA-VCA titer is sensitive for the diagnosis of NPC, it should not be used as the sole means of screening for NPC in a population in which NPC is endemic.

Cited by 45 publications

References 7 publications

EA-D p45-IgG as a Potential Biomarker for Nasopharyngeal Carcinoma Diagnosis

EA-D p45-IgG as a Potential Biomarker for Nasopharyngeal Carcinoma Diagnosis

Plasma Epstein‐Barr virus (EBV) DNA: Role as a screening test for nasopharyngeal carcinoma (NPC)?

Systematic Review on Epstein-Barr Virus (EBV) DNA in Diagnosis of Nasopharyngeal Carcinoma in Asian Populations

Contact Info

Product

Resources

About